2.48
0.00%
0.00
After Hours:
2.48
Acumen Pharmaceuticals Inc stock is traded at $2.48, with a volume of 89,495.
It is up +0.00% in the last 24 hours and down -9.49% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$2.48
Open:
$2.48
24h Volume:
89,495
Relative Volume:
0.25
Market Cap:
$147.80M
Revenue:
-
Net Income/Loss:
$-52.37M
P/E Ratio:
-2.1754
EPS:
-1.14
Net Cash Flow:
$-43.09M
1W Performance:
+4.64%
1M Performance:
-9.49%
6M Performance:
-38.77%
1Y Performance:
-40.24%
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
925-368-8508
Address
427 PARK ST., CHARLOTTESVILLE
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-20-23 | Resumed | BofA Securities | Buy |
May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
Jul-15-22 | Initiated | BTIG Research | Buy |
Jun-30-22 | Initiated | H.C. Wainwright | Buy |
Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
Jul-26-21 | Initiated | BofA Securities | Neutral |
Jul-26-21 | Initiated | Credit Suisse | Outperform |
Jul-26-21 | Initiated | Stifel | Buy |
Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - Marketscreener.com
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - EIN News
Comprehensive Analysis of Growth Drivers and Challenges in the Neurological Biomarkers Market In New Report - WhaTech
ABOSAcumen Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Acumen extends Alzheimer's drug partnership with Lonza By Investing.com - Investing.com Australia
Acumen extends Alzheimer's drug partnership with Lonza By Investing.com - Investing.com South Africa
Acumen extends Alzheimer's drug partnership with Lonza - Investing.com India
Acumen extends Alzheimer's drug partnership with Lonza - Investing.com
Acumen extends Alzheimer's drug partnership with Lonza By Investing.com - Investing.com Canada
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer's Disease - The Manila Times
Acumen extends collaboration with Lonza - TipRanks
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for - EIN News
Acumen Health Holdings to Acquire Avenova Brand Enhancing Eye Health Portfolio - MSN
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024 - StockTitan
Acumen Health Holdings to Acquire Avenova Brand Enhancing Eye Health Portfolio - MyChesCo
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - StockTitan
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - Yahoo Finance
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Large Drop in Short Interest - MarketBeat
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer - Quantisnow
Acumen Pharmaceuticals (NASDAQ:ABOS) Shares Up 9.9% - MarketBeat
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference - StockTitan
Perhaps timely catching Acumen Pharmaceuticals Inc (ABOS) would be a good idea - SETE News
Acumen Pharmaceuticals Inc (ABOS) stock: A year of ups and downs - US Post News
ABOS’s Market Whiplash: -28.65% YTD Decline, -15.17% Plunge in 30 Days - The InvestChronicle
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Industrials Capped Index (TTIN) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
2 'Strong Buy'-Rated Stocks That Wall Street Believes Can Soar Over 360% - Inkl
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
2 'Strong Buy'-Rated Stocks That Wall Street Believes Can Soar Over 360% - Nasdaq
Vanguard Group Inc. Sells 174,494 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
HC Wainwright Comments on Acumen Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:ABOS) - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - Defense World
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Grows By 12.7% - MarketBeat
Acumen Pharmaceuticals (NASDAQ:ABOS) Receives “Buy” Rating from HC Wainwright - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) PT Lowered to $6.00 - MarketBeat
BTIG maintains Buy rating on Acumen stock amid trial progress By Investing.com - Investing.com Australia
Acumen Pharmaceuticals (NASDAQ:ABOS) Posts Earnings Results, Misses Expectations By $0.06 EPS - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results - MarketBeat
BTIG maintains Buy rating on Acumen stock amid trial progress - Investing.com India
BTIG maintains Buy rating on Acumen stock amid trial progress - Investing.com
BTIG maintains Buy rating on Acumen stock amid trial progress By Investing.com - Investing.com UK
Acumen Pharmaceuticals (NASDAQ:ABOS) Receives Buy Rating from HC Wainwright - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Acumen Pharmaceuticals reports on Q2 2024 progress By Investing.com - Investing.com Australia
Earnings call: Acumen Pharmaceuticals reports on Q2 2024 progress - Investing.com
Earnings call: Acumen Pharmaceuticals reports on Q2 2024 progress - Investing.com India
Earnings call: Acumen Pharmaceuticals reports on Q2 2024 progress By Investing.com - Investing.com UK
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q2 2024 - InvestorPlace
Acumen Pharmaceuticals Unveils Updated Corporate Presentation and Financials - TipRanks
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights - StockTitan
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):